{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T09:15:41Z","timestamp":1719998141381},"reference-count":28,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> DAV\u2010interferon (IFN)\u2010\u03b2 therapy is a combination chemotherapy of dacarbazine (<jats:styled-content>D<\/jats:styled-content>TIC), nimustine (<jats:styled-content>A<\/jats:styled-content>CNU) and vincristine (<jats:styled-content>V<\/jats:styled-content>CR) with local subcutaneous injection of IFN\u2010\u03b2 that is widely employed as postoperative adjuvant chemotherapy to treat malignant melanoma in Japan. However, the efficacy of DAV\u2010IFN\u2010\u03b2 therapy has not been confirmed by randomized controlled trials and the benefit of DAV\u2010IFN\u2010\u03b2 therapy has not been established yet. This study evaluated the contribution of DAV\u2010IFN\u2010\u03b2 therapy to improve survival of postoperative patients with cutaneous melanoma.<\/jats:p><jats:p><jats:bold>Methods<\/jats:bold> Patients with stage II or III cutaneous melanoma seen at Nagoya University Hospital from January 1998 to December 2009 were eligible for this study. Disease\u2010free survival rates and melanoma\u2010specific survival rates were evaluated. A propensity score was calculated to control for the effects of variables related to decisions regarding the application of DAV\u2010IFN\u2010\u03b2 therapy.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Eighty\u2010two stage II and 60 stage III melanoma patients were included. In the post\u2010matched stage II patients (17 matched pairs), the mean (\u00b1SE) disease\u2010free survival rates were 39.9\u00b113.7% for DAV\u2010IFN\u2010\u03b2 therapy and 73.1\u00b111.7% for non\u2010use (hazard ratio for recurrence, 2.06; 95% CI, 0.63\u20136.69; <jats:italic>P<\/jats:italic>\u2003=\u20030.23), and the melanoma\u2010specific survival rates were 66.2\u00b120.0% for DAV\u2010IFN\u2010\u03b2 therapy and 86.2\u00b19.1% for non\u2010use (hazard ratio for death, 1.09; 95% CI, 0.17\u20136.82; <jats:italic>P<\/jats:italic>\u2003=\u20030.93). In the post\u2010matched stage III patients (nine matched pairs), the disease\u2010free survival rates were 29.6\u00b116.4% for DAV\u2010IFN\u2010\u03b2 therapy and 33.3\u00b115.7% for non\u2010use (0.69; 95% CI, 0.22\u20132.17; <jats:italic>P<\/jats:italic>\u2003=\u20030.53), and the melanoma\u2010specific survival rates were 55.6\u00b116.6% for DAV\u2010IFN\u2010\u03b2 therapy and 44.4\u00b116.6% for non\u2010use (0.67; 95% CI, 0.18\u20132.50; <jats:italic>P<\/jats:italic>\u2003=\u20030.55).<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> DAV\u2010IFN\u2010\u03b2 therapy brought no significant improvement in either disease\u2010free survival rates or melanoma\u2010specific survival rates of patients with stage II or III cutaneous melanoma. A randomized controlled trial would be required to further evaluate the efficacy of DAV\u2010IFN\u2010\u03b2 therapy as an adjuvant chemotherapy.<\/jats:p>","DOI":"10.1111\/jdv.12040","type":"journal-article","created":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T06:52:07Z","timestamp":1354344727000},"page":"1514-1520","source":"Crossref","is-referenced-by-count":17,"title":["Postoperative DAV\u2010IFN\u2010\u03b2 therapy does not improve survival rates of stage II and stage III melanoma patients significantly"],"prefix":"10.1111","volume":"27","author":[{"given":"T.","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Sakakibara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Yasue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Yatsuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,12]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.5227\/skincancer.4.349"},{"key":"e_1_2_5_3_2","first-page":"41","article-title":"Clinical research into the use of human fibroblast interferon (Hu IFN\u2010\u03b2) to treat malignant skin neoplasia","volume":"18","author":"Ishihara K","year":"1983","journal-title":"J Jpn Soc Cancer Ther"},{"key":"e_1_2_5_4_2","first-page":"73","article-title":"Clinical study of DAV + IFN\u2010\u03b2 therapy (combination adjustment therapy with intravenous DTIC, ACNU and VCR, and local injection of IFN\u2010\u03b2) for malignant melanoma","volume":"12","author":"Yamamoto A","year":"1996","journal-title":"Int J Immunother"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810601)47:11<2556::AID-CNCR2820471107>3.0.CO;2-J"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198210073071503"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/jso.2930360404"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1992.01420040034005"},{"key":"e_1_2_5_9_2","first-page":"453","volume-title":"Ann Surg","author":"Morton DL","year":"1999"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06133.x"},{"key":"e_1_2_5_11_2","first-page":"302","volume-title":"Ann Surg","author":"Morton DL","year":"2005"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2010.00856.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.039"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.04.165"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.1551"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi190"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.0483"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj138"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm331"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.10.8217"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.8288"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.4.12.2205"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.1.7"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.12.2444"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-1103-3"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3181f20bb1"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.1627"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.2010.115"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e318214beba"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12040","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12040","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.12040","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T05:15:01Z","timestamp":1696223701000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.12040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.1111\/jdv.12040"],"URL":"https:\/\/doi.org\/10.1111\/jdv.12040","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}